蝶腭神经节刺激增加脑血流:随机假对照试验
这项在7国41中心开展的随机假对照双盲试验,纳入未接受再灌注治疗的急性前循环缺血性卒中患者,评估蝶腭神经节刺激的疗效与安全性。主要终点90天改良Rankin量表超预期改善率在SPG组与假组分别为49.7%与40.0%(OR 1.48,95%CI 0.89-2.47,P=0.13)。在确认皮层受累的87例患者中,改善率分别为50.0%与27.0%(OR 2.70,95%CI 1.08-6.73,P=0.03)。
要点
- SPG刺激在急性缺血性卒中24小时内使用是安全的。
- 总体人群主要终点未达统计学显著,但SPG组数值更高。
- 确认皮层受累患者中SPG刺激显示名义显著获益。
核心结论
- SPG刺激在急性缺血性卒中发病24小时内是安全的,但未显示统计学显著改善90天残疾超预期率,仅在确认皮层受累患者中观察到名义显著获益。
研究设计与样本
- 随机、假对照、双盲试验,在7国41中心开展,纳入前循环缺血性卒中未接受再灌注治疗且发病24小时内患者。
- 计划样本量660例,因器械置放技术改进提前终止;改良意向治疗人群253例(SPG组153例,假组100例)。
主要发现
- 主要终点90天改良Rankin量表超预期改善率:SPG组49.7% vs 假组40.0%,OR 1.48(95%CI 0.89-2.47),P=0.13。
- 卒中部位(皮层 vs 非皮层)与治疗交互作用显著,P=0.04。
- 确认皮层受累的87例患者中,超预期改善率SPG组50.0% vs 假组27.0%,OR 2.70(95%CI 1.08-6.73),P=0.03。
- 所有预设次要疗效终点呈现相似反应模式;死亡率和严重不良事件安全终点无差异。
关键数值与推荐
- 改良意向治疗人群年龄中位73岁(IQR 64-79),女性52.6%,NIHSS中位11(IQR 9-15),最后已知良好时间中位18.6小时(IQR 14.5-22.5)。
临床怎么用
- SPG刺激可作为急性缺血性卒中不适合再灌注治疗患者的安全辅助策略,尤其对确认皮层受累者可能获益。
- 需在更大规模关键试验中确认疗效后方可常规临床应用。
局限性
- 试验因器械置放技术改进提前终止,实际样本量远低于计划,可能影响统计效能。
- 主要终点总体未达统计学显著,皮层受累亚组获益为名义显著,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Many patients with acute ischemic stroke are not eligible for thrombolysis or mechanical reperfusion therapies due to contraindications, inaccessible vascular occlusions, late presentation, or large infarct core. Sphenopalatine ganglion (SPG) stimulation to enhance collateral flow and stabilize the blood-brain barrier offers an alternative, potentially more widely deliverable, therapy. Methods- In a randomized, sham-controlled, double-masked trial at 41 centers in 7 countries, patients with anterior circulation ischemic stroke not treated with reperfusion therapies within 24 hours of onset were randomly allocated to active SPG stimulation or sham control. The primary efficacy outcome was improvement beyond expectations on the modified Rankin Scale of global disability at 90 days (sliding dichotomy), assessed in the modified intention-to-treat population. The initial planned sample size was 660 patients, but the trial was stopped early when technical improvements in device placement occurred, so that analysis of accumulated experience could be conducted to inform a successor trial. Results- Among 303 enrolled patients, 253 received at least one active SPG or sham stimulation, constituting the modified intention-to-treat population (153 SPG stimulation and 100 sham control). Age was median 73 years (interquartile range, 64-79), 52.6% were female, deficit severity on the National Institutes of Health Stroke Scale was median 11 (interquartile range, 9-15), and time from last known well median 18.6 hours (interquartile range, 14.5-22.5). For the primary outcome, improved 3-month disability beyond expectations, rates in the SPG versus sham treatment groups were 49.7% versus 40.0%; odds ratio, 1.48 (95% CI, 0.89-2.47); P=0.13. A significant treatment interaction with stroke location (cortical versus noncortical) was noted, P=0.04. In the 87 patients with confirmed cortical involvement, rates of improvement beyond expectations were 50.0% versus 27.0%; odds ratio, 2.70 (95% CI, 1.08-6.73); P=0.03. Similar response patterns were observed for all prespecified secondary efficacy outcomes. No differences in mortality or serious adverse event safety end points were observed. Conclusions- SPG stimulation within 24 hours of onset is safe in acute ischemic stroke. SPG stimulation was not shown to statistically significantly improve 3-month disability above expectations, though favorable outcomes were nominally higher with SPG stimulation. Beneficial effects may distinctively be conferred in patients with confirmed cortical involvement. The results of this study need to be confirmed in a larger pivotal study. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT03767192.
引用
- Bornstein NM, Saver JL, Diener HC, et al. Sphenopalatine Ganglion Stimulation to Augment Cerebral Blood Flow: A Randomized, Sham-Controlled Trial. Stroke. 2019. PMID: 31117920. doi:10.1161/STROKEAHA.118.024582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。